Top Page
Creo Medical
(LSE:CREO)
Creo Medical (CREO) vs. iShares MSCI United Kingdom ETF (EWC)
Creo Medical Business Overview & Revenue Model
Creo Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.30M | 4.00M | 30.80M | 27.17M | 25.16M | 9.43M |
| Gross Profit | 15.00M | 1.90M | 15.30M | 10.01M | 9.02M | 2.44M |
| EBITDA | -22.30M | -26.10M | -20.70M | -27.62M | -27.54M | -21.77M |
| Net Income | -22.40M | -28.70M | -21.70M | -26.94M | -24.59M | -20.32M |
Balance Sheet | ||||||
| Total Assets | 69.30M | 65.00M | 76.60M | 75.34M | 100.61M | 92.46M |
| Cash, Cash Equivalents and Short-Term Investments | 9.80M | 8.70M | 18.50M | 13.10M | 43.53M | 45.09M |
| Total Debt | 14.20M | 4.40M | 8.30M | 10.10M | 10.56M | 12.36M |
| Total Liabilities | 21.90M | 22.60M | 16.80M | 25.93M | 27.29M | 29.66M |
| Stockholders Equity | 47.40M | 42.40M | 59.80M | 49.40M | 73.32M | 62.81M |
Cash Flow | ||||||
| Free Cash Flow | -21.40M | -22.60M | -23.20M | -28.26M | -32.10M | -16.66M |
| Operating Cash Flow | -20.10M | -22.20M | -21.60M | -24.99M | -25.98M | -16.09M |
| Investing Cash Flow | 13.70M | 15.30M | -18.30M | -6.03M | -7.87M | -21.16M |
| Financing Cash Flow | 4.70M | 16.20M | 29.80M | 522.00K | 31.99M | 1.33M |
Creo Medical Technical Analysis
Creo Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | £20.66M | ― | -2.91% | ― | -5.33% | 60.20% | |
55 Neutral | £7.06M | 1,137.50 | 0.08% | ― | 87.72% | ― | |
51 Neutral | $7.86B | -0.33 | -41.39% | 2.23% | 23.26% | -2.03% | |
51 Neutral | £54.65M | ― | -38.49% | ― | ― | ― | |
48 Neutral | £20.62M | ― | -65.64% | ― | 1.65% | -102.83% | |
| ― | £3.01M | ― | -85.77% | ― | ― | ― | |
| ― | £66.64M | ― | -430.02% | ― | ― | ― |
Creo Medical Corporate Events
Creo Medical Group has highlighted the successful use of its Speedboat® technology through a testimonial from Liz Thomas, who avoided major surgery thanks to the procedure. This case underscores the clinical value of Speedboat® in treating early-stage colorectal cancer and its potential to reduce surgical burdens. The ongoing pilot with the Aneurin Bevan University Health Board in Wales is showing promising results, which could lead to broader adoption across the NHS, supporting Creo’s growth strategy.
Creo Medical Group PLC announced the acquisition of 228,940 ordinary shares by Fiduchi Trustees under its Share Incentive Plan, with executive directors Craig Gulliford and Richard Rees participating. This move aligns with the company’s strategy to incentivize its UK-based employees and directors, reflecting its commitment to enhancing shareholder value and maintaining a robust equity structure without issuing new shares.
Creo Medical Group reported a 40% increase in core technology revenue for the first half of 2025, aligning with management expectations and projecting continued growth. The company has achieved significant operational efficiencies, reducing costs and losses, and has strengthened its financial position with increased cash reserves. Recent regulatory approvals and strategic partnerships, particularly in the US market, are expected to drive further adoption of its advanced energy products. The sale of a 51% interest in Creo Medical Europe and the divestment of part of its Chepstow site are strategic moves to enhance cash flow and streamline operations. The company remains optimistic about its growth prospects and aims to improve outcomes for pre-cancer and cancer patients worldwide.
Creo Medical Group has initiated a landmark post-market clinical study to evaluate the safety and performance of its MicroBlate™ Flex device for treating lung tumors. This study, conducted in the Netherlands and the UK, is part of Creo’s growth strategy to gather substantial clinical data ahead of commercializing the device, which offers a less invasive treatment option for lung cancer patients. The collaboration with Intuitive highlights Creo’s position in minimally invasive lung cancer treatment and the potential impact of MicroBlate™ Flex on the industry.
Creo Medical Group has announced a revision in the exercise price of options granted to its CEO and CFO, increasing the price from £0.13125 to £0.24 per share. This decision, made after consulting significant shareholders, reflects the company’s commitment to aligning management incentives with shareholder interests, potentially impacting the company’s financial strategies and stakeholder relations.
Creo Medical Group plc has announced a change in its Nominated Adviser and Broker from Numis Securities Limited to Deutsche Bank AG, London Branch. This change follows the acquisition of Numis Securities’ parent company by Deutsche Bank AG. The shift is expected to impact Creo Medical’s operations by aligning with a globally recognized financial institution, potentially enhancing its market positioning and stakeholder confidence.
Creo Medical Group plc has announced a change in its Nominated Adviser and Broker from Numis Securities Limited to Deutsche Bank AG, London Branch, following the acquisition of Numis’s parent company by Deutsche Bank. This change is expected to support Creo’s strategic operations and potentially enhance its market positioning by aligning with a globally recognized financial institution.
Creo Medical Group plc announced that all resolutions proposed at its Annual General Meeting were successfully passed, reflecting shareholder support for the company’s strategic direction. This outcome reinforces Creo’s position in the medical device industry, particularly in the minimally invasive surgical endoscopy market, potentially enhancing its operational capabilities and stakeholder confidence.
Creo Medical Group, a leader in minimally invasive surgical endoscopy, announced significant progress and strategic changes at its AGM. The company is focusing on cost reduction and revenue growth from its core technology, with recent FDA clearance for its SpydrBlade Flex device enhancing its market position. Board changes reflect a strategy to strengthen governance and commercial leadership, aiming for accelerated growth and improved financial performance.
Creo Medical Group has received U.S. FDA clearance for its SpydrBlade™ Flex, a versatile endoscopic device designed for precision in therapeutic endoscopy procedures. This clearance allows Creo to launch the device in the U.S. market, supported by its existing sales network and recent reimbursement code decisions by the American Medical Association. The SpydrBlade™ Flex, part of Creo’s advanced energy GI product range, is expected to enhance the company’s market position by offering a unique solution for complex surgical procedures, potentially benefiting patients, clinicians, and healthcare providers.
Creo Medical Group PLC announced that its Non-Executive Chairman, Kevin T. Crofton, has acquired 701,750 ordinary shares of the company at an average price of 15.75 pence per share. This transaction, conducted on the London Stock Exchange, increases Crofton’s total shareholding to 5,447,416 shares, representing 1.32% of voting rights. The acquisition signifies confidence in the company’s strategic direction and could positively influence stakeholder perceptions and market positioning.
Creo Medical Group plc has published its 2024 Annual Report and Accounts along with the Notice of its Annual General Meeting (AGM) on its website. The AGM is scheduled for 26 June 2025, where shareholders are encouraged to vote by proxy due to potential unforeseen circumstances. This announcement underscores the company’s commitment to transparency and shareholder engagement, while also highlighting its strategic focus on minimally invasive surgical endoscopy for cancer patients.
Creo Medical Group plc has announced a significant milestone with the American Medical Association’s approval of two new Category I CPT reimbursement codes for Endoscopic Submucosal Dissection (ESD) procedures in the U.S. This development is expected to enhance access to advanced, minimally invasive surgical options for patients with early-stage cancerous and pre-cancerous lesions in the gastrointestinal tract. The new reimbursement framework is anticipated to drive broader adoption of ESD procedures, benefiting approximately 5% of the U.S. population over 50 who could potentially benefit from such treatments. Additionally, this milestone is set to encourage the use of Creo’s next-generation products, such as Speedboat® UltraSlim, furthering medical innovation and improving patient outcomes.
Creo Medical Group PLC has announced a change in its major holdings, with M&G Plc increasing its voting rights from 10.12% to 11.51%. This acquisition of voting rights by M&G Plc signifies a strengthened position in the company, potentially impacting its strategic decisions and influencing shareholder dynamics.
Creo Medical Group PLC has announced a significant change in its shareholder structure, with M&G Plc increasing its voting rights from 5.54% to 10.12%. This acquisition of voting rights by M&G Plc, a major investment company based in London, indicates a strengthened position in Creo Medical, potentially impacting the company’s strategic decisions and signaling confidence in its market potential.
Creo Medical Group plc announced the retirement of John Bradshaw, its Senior Independent Non-Executive Director, who has been with the company since its IPO in 2016. Ivonne Cantu will serve as interim Audit Committee chair, while Brent Boucher will take over as Remuneration Committee chair. These changes are part of Creo’s ongoing efforts to strengthen its governance framework and ensure a smooth leadership transition.
Creo Medical Group plc announced the retirement of John Bradshaw, its Senior Independent Non-Executive Director, who has been with the company since its IPO in 2016. Ivonne Cantu will temporarily chair the Audit Committee until a permanent replacement is found, while Brent Boucher will take over as the Remuneration Committee chair. These changes are part of Creo’s ongoing efforts to strengthen its governance framework as it continues to innovate in the field of minimally invasive surgical endoscopy.
Creo Medical Group PLC reported strong financial results for FY24, with a significant 74% increase in Core Technology revenues driven by the commercial rollout of Speedboat UltraSlim. The company’s strategic moves, including the sale of a 51% stake in Creo Medical Europe and cost management efforts, have strengthened its balance sheet. The company is optimistic about future growth, targeting a 40%-60% increase in Core Technology revenue for FY25, supported by new product launches and strategic partnerships.